<!DOCTYPE html>

<html>
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<link href="../../../webpages.css" rel="stylesheet"/>
</head>
<body>
<div class="banner">
<div class="banner-content">
<h1>DermpathNet</h1>
</div>
</div>
<nav>
<a href="../../../index.html" target="_blank">
<text type="button">Home</text>
</a>
<a href="../../../browser-page-317.html" target="_blank">
<text type="button">Browse</text>
</a>
<a href="../../../download-page.html" target="_blank">
<text type="button">Downloads</text>
</a>
<a href="../../../contact-us.html" target="_blank">
<text type="button">About</text>
</a>
</nav>
<footer class="site-footer">
<p>@2024 New York University Grossman School of Medicine, Weill Cornell Medicine</p>
<!--<p>Privacy Policy | Terms of Service | Cookie Policy</p>-->
</footer>
<title>A Review of Key Biological and Molecular Events Underpinning Transformation of Melanocytes to Primary and Metastatic Melanoma.-DermPath</title>
<div class="content-container"> <div class="figures-container"> <div class="image-side"> <img alt="A Review of Key Biological and Molecular Events Underpinning Transformation of Melanocytes to Primary and Metastatic Melanoma." class="clickable-image" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e338/6966527/971067f8e3df/cancers-11-02041-g009.jpg"/> </div> <div class="text-side"> <h1>A Review of Key Biological and Molecular Events Underpinning Transformation of Melanocytes to Primary and Metastatic Melanoma.</h1> <p>Metastatic melanoma. (A) H&amp;E × 12.5. In transit metastasis. Tumor metastasis is dependent on critical factors that drive tumor cell motility, dissemination into angiolymphatics, and tumor cell proliferation away from the primary site. (B) H&amp;E × 40. Targeted therapy and immunotherapy have heralded a revolutionary era in melanoma management. Pathological response manifests variably as tumor cell necrosis, melanosis, lymphocytic infiltration and fibrosis, as seen in this lymph node metastasis of melanoma after neoadjuvant therapy. Mechanisms of resistance and primary non-response are the focus of active research.</p> <p>PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/31861163/" target="_blank">31861163</a></p><p>Type: Premalignant/Malignant, Category: Melanocytic</p>
</div> </div></div></body></html>